UTRECHT, THE NETHERLANDS, 4 March 2016 – The Laboratory for Translational and Molecular Imaging (LTMI) at the Duke-NUS Medical School in Singapore will install a MILabs VECTor4CT system located inside their specific pathogen free – SPF – barrier facility. A major thrust of LTMI is to develop in vivo molecular imaging agents to study cancer biology, inflammation, infection, and brain and immune function, with an Asian disease-centric focus. Current research projects are supported by funding from the Singapore National Research Foundation, Singapore National Medical Research Council, and a number of industrial partners.
The proximity to Singapore General Hospital, the National Cancer Centre Singapore and other medical research centres, gives Duke-NUS LTMI the unique advantage of being ideally located to encourage collaboration between biomedical sciences, translational research, and clinical applications.
The head of LTMI is Dr. Ann-Marie Chacko, an Assistant Professor in the Duke-NUS Cancer and Stem Cell Biology Programme, and an Adjunct Faculty with the SingHealth Nuclear Medicine Residency Programme. The installation of the VECTor4CT at Duke-NUS solidifies her vision to establish LTMI as a core facility for Duke-NUS researchers, and as a resource accessible to the broader Singapore research community, from other academic institutes to industry groups. LTMI will drive emerging imaging and technology research, including PET/CT and SPECT/CT, and drug development through contract work and collaborations.
Ad Statistics
Times Displayed: 3899
Times Visited: 9 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
According to Dr. Chacko, the ability of the system to perform simultaneous PET and SPECT of co-injected tracers combined with fast dynamic acquisitions, are key differentiating performance characteristics that will enable researchers to expand the scope and breadth of translational imaging applications.
It is anticipated that these innovative molecular imaging capabilities will bring significant benefits to Duke-NUS researchers, and the broader Singapore community, across the spectrum of diseases.
About Duke-NUS Medical School
The Duke-NUS Medical School (Duke-NUS) was established in 2005 as a strategic collaboration between the Duke University School of Medicine, located in North Carolina, USA, and the National University of Singapore (NUS). Duke-NUS offers a graduate-entry, 4-year MD (Doctor of Medicine) training programme based on the unique Duke model of education, with one year dedicated to independent study and research projects of a basic science or clinical nature. Duke-NUS also offers MD/PhD and PhD programmes. Duke-NUS has five Signature Research Programmes: Cancer and Stem Cell Biology, Neuroscience and Behavioural Disorders, Emerging Infectious Diseases, Cardiovascular and Metabolic Disorders, and Health Services and Systems Research.
